SynthesisFrontiers in pharmacology2026
Protective effects of resveratrol in animal models of chronic obstructive pulmonary disease: a preclinical systematic review and meta-analysis.
Synthesis in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This systematic review and meta-analysis aimed to quantitatively evaluate the protective effects of resveratrol (RES) in animal models of chronic obstructive pulmonary disease (COPD) and systematically summarize its potential molecular regulatory mechanisms. Methods: Eight databases were systematically searched for eligible animal studies from inception to February 2026. Methodological quality was assessed using the SYRCLE tool. Meta-analyses were performed using Review Manager 5.4 and Stata 18.0. Results: This meta-analysis included 14 preclinical studies involving a total of 377 experimental animals (experimental group: 239; control group: 138). The results showed that RES significantly alleviated airflow limitation and improved pulmonary function in COPD models (FEV Conclusion: Current preclinical evidence suggests that RES may improve pulmonary function and attenuate inflammatory responses and oxidative stress-related injury in COPD animal models. However, these findings should be considered preliminary, and further well-designed studies are needed to validate the translational relevance of RES in COPD. Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD420261309405, identifier CRD420261309405.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.